Moderna Third-Quarter Earnings Show Soaring Revenue, R&D Costs

Moderna Third-Quarter Earnings Show Soaring Revenue, R&D Costs

Moderna posted third-quarter results early Thursday that showed revenue jumping more than 800% but R&D costs tripling as the company strives to develop its Covid-19 vaccine; MRNA stock rose.